Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+, Mozilla Firefox 20+, Internet Explorer 11, Opera 15–18, Apple Safari 7, SeaMonkey 2.15-2.23

Become a member
  1. OncologyPRO
  2. Meeting Resources
  3. ESMO Congress 2021

ESMO Colloquium supported by Eisai Europe Ltd - How to optimise efficacy and safety of targeted agent/IO management strategies in advanced solid tumours: Single agents, combinations and biomarkers

Optimal selection of patients with untreated advanced hepatocellular cancer for combination and monotherapy regimens: Agents, combinations and emerging biomarkers

Date

18 Sep 2021

Session

ESMO Colloquium supported by Eisai Europe Ltd - How to optimise efficacy and safety of targeted agent/IO management strategies in advanced solid tumours: Single agents, combinations and biomarkers

Presenters

Masafumi Ikeda

Authors

M. Ikeda

Author affiliations

  • Hepatobiliary & Pancreatic Oncology Dept., National Cancer Center Hospital East, 277-8577 - Kashiwa/JP

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Login

Resources from the same session

Q&A and live discussion

Presenter: Jens Bedke

Session: ESMO Colloquium supported by Eisai Europe Ltd - How to optimise efficacy and safety of targeted agent/IO management strategies in advanced solid tumours: Single agents, combinations and biomarkers

Resources:

Slides

Webcast

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings

  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.